Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix™ vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years
One month after the booster dose: To evaluate the immunogenicity of GSK Biologicals’ dTpa vaccine, in terms of antibody response to all vaccine antigens. To assess the immunogenicity of the Chinese ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Safety and immunogenicity study of a prime-boost schedule of GSK Biologicals' influenza vaccine GSK1562902A in children aged 3 to 17 years
Co-primary Immunogenicity Objective • To assess the superiority of the haemagglutination inhibition (HI) antibody response against A/turkey/Turkey/01/2005 (H5N1) 10 days following H5N1 vaccination at...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A PMS study to assess the safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib and INFANRIX HEXA™ vaccines when administered as a primary vaccination course, followed by admini-stration of GSK Biologicals’ DTPa-IPV/Hib vaccine as a booster dose in toddlers
To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity, safety and reactogenicity of GSK Biologicals’ Hib-MenCY-TT vaccine 792014 compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) vaccine in healthy infants and toddlers
•To demonstrate non-inferiority of 4 doses of Hib-MenCY-TT compared to 3 doses of PedvaxHIB,when co-administered with Prevnar 13 and Havrix,in terms of anti-PRP concentration Epoch 001:To demonstrate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or PrevenarTM in study 10PN-PD-DIT-003 (105554), via the administration of a single booster dose of a 23-valent pneumococcal plain polysaccharide vaccine
To assess the immunological memory following primary vaccination with either GSK Biologicals’ 10-valent conjugate vaccine or Prevenar™, through the administration of a single booster dose of unconjuga...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of Infanrix hexa in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery
To assess the immunological response to DTPa-HBV-IPV/Hib in terms of seroprotection status for diphtheria, tetanus, hepatitis B, poliovirus and Hib antigens, and in terms of vaccine response to the pe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella (MMR) vaccine in children in their second year of life. GlaxoSmithKline (GSK) Biologicalsin tuhkarokko-sikotautivihurirokkorokotteen (MMR) immunogeenisuus- ja turvallisuustutkimus lapsilla toisen ikävuoden aikana
•To demonstrate non-inferiority of Inv_MMR vaccine compared to pooled Com_MMR vaccine lots in terms of seroresponse rates to MMR viruses at Day 42. •To demonstrate non-inferiority of Inv_MMR vaccine ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, observer-blind, multicountry, multicentre, randomized study to demonstrate the non-Inferiority of GlaxoSmithKline Biologicals’ one-container AS25 adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals’ two-container AS25 adjuvanted influenza vaccine in adults aged 65 years and above
To demonstrate the immunological non-inferiority (in terms of HI antibody GMT) of the one container presentation of the AS25 adjuvanted influenza vaccine from the NH 2006/07 season (FluAS25 -1 contain...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given in healthy infants at 3, 5 and 11 months of age
To demonstrate that GSK Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine (Combo group) is non-inferior to GSK Biologicals’ DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine co-administered with Novartis’ meningoc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2, 4 and 12 months of age
-To demonstrate non-inferiority of the DTPa-HBV-IPV/Hib-MenC-TT vaccine when compared to the control group, in terms of immune response to Hib and MenC antigens, one month after the second vaccine dos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
10
11
12
13
14
15
16
17
18
19
Suivant